Details for Patent: 8,865,698

Which drugs does patent 8,865,698 protect, and when does it expire?

Patent 8,865,698 protects VITRAKVI and is included in two NDAs.

This patent has one hundred and fourteen patent family members in thirty-nine countries.

Summary for Patent: 8,865,698

Title:	Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Abstract:	Provided herein are methods for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal, which comprises administering to said mammal in need thereof a therapeutically effective amount of a compound of Formula I: in which R1, R2, R3, R4, X, Y and n have the meanings given in the specification.
Inventor(s):	Julia Haas, Steven W. Andrews, Yutong Jiang, Gan Zhang
Assignee:	Array Biopharma Inc
Application Number:	US13/943,590
Patent Claim Types: see list of patent claims	Use;

United States Patent 8,865,698 (Method Claims for Formula I Compounds): Scope, Claim Construction Risks, and US Patent Estate Map

US Patent 8,865,698 is a broad US method-of-treatment patent that claims therapeutic use of a large genus of “Formula I” chiral compounds (and pharmaceutically acceptable salts) to treat pain, cancer, inflammation, neurodegenerative disease, or Trypanosoma cruzi infection. The independent claim is drafted as a functional genus with extensive Markush-style latitude across multiple substituent variables, plus additional claim sets that narrow certain linkage options, substituent ranges, salt forms, and enumerated exemplar compounds. The practical scope risk is claim breadth versus enforceability: the claim covers many compound structures that may or may not be supported by enablement and known structure-activity relationships depending on the specification. The portfolio impact is strongest for enforcing method-of-use rights against US-administered products using covered Formula I structures, while product-formulation and manufacturing workarounds do not fully avoid infringement because the claim is directed to treating a mammal via administration of the covered compound.

---

What does US Patent 8,865,698 claim and how broad is the “Formula I” genus?

Answer: Claim 1 is a method-of-treatment claim covering administration (therapeutically effective amount) of any Formula I compound (or pharmaceutically acceptable salt) to treat five therapeutic indications, with very broad substituent freedom across R1, R2, Rb/Rc ring definitions, Y aryl/heteroaryl, linker X, and multiple stereochemical and ring-size options (4- to 8-membered heterocycles).

Indications covered by Claim 1

Claim 1 expressly covers methods for treating:

• pain
• cancer
• inflammation
• neurodegenerative disease
• Trypanosoma cruzi infection

This is unusually wide for a single method claim; it increases the likelihood that method-of-use infringement theories can map to multiple clinical indications of the same drug candidate.

Core claim structure: administration of a Formula I compound

Claim 1 is structured as:

• treat a mammal with a therapeutically effective amount
• administer a compound “of Formula I or a pharmaceutically acceptable salt”
• Formula I parameters are defined by nested Markush variables and ring constructors:
  • R1
  • R2
  • Rb and Rc
  • heterocycle ring-size classes built from NRbRc
  • heteroaryl substituents hetAr1/hetAr2/hetAr3/hetCyc1/hetCyc2
  • aryl/heteroaryl Y
  • linker X
  • stereochemical “absolute configuration of Figure Ia”
  • additional parameters Re/Rf/Rg plus piperazine/azacyclic fragments (via the variable definitions embedded into the genus)

Breadth drivers: Markush freedom and functional class definitions

Key breadth components:

• R1: H or (1-6C alkyl)
• R2: a very large set, including:
  • NRbRc
  • (1-4C)alkyl / (1-4C)fluoroalkyl
  • CF3
  • (1-4C)hydroxyalkyl
  • -(1-4C alkyl)hetAr1
  • -(1-4C alkyl)NH2 / -(1-4C alkyl)NH(1-4C alkyl) / -(1-4C alkyl)N(1-4C alkyl)2
  • heteroaryl groups hetAr2
  • azacyclic groups hetCyc1/hetCyc2
  • phenyl optionally substituted with NHSO2(1-4C alkyl)
  • (3-6C)cycloalkyl optionally substituted with CN, OH, OMe, amines, halogens, CF3, carboxylates/acids, amides, or esters
• Ring constructors via NRbRc:
  • 4-membered N heterocycles, optionally substituted
  • 5-6 membered N heterocycles, optionally second heteroatom group selected from N/O/SO2
  • 7-8 membered bridged N heterocycles, optionally second heteroatom selected from N/O
• Y:
  • phenyl optionally substituted with halogen, (1-4C)alkoxy, CF3, CHF2; or
  • 5-6 membered heteroaryl with N and S, with optional halogens
• X: null, -CH2-, -CH2CH2-, -CH2O-, or -CH2NRd-
• n: 0 to 6 in Claim 1; later dependent claims narrow to 0-2, and X and Y subsets appear in dependent claim ladders.

Net effect: Claim 1 covers a large chemical space centered on a shared core scaffold (pyrazolo[1,5-a]pyrimidine substituted with a pyrrolidine-containing moiety and a stereodefined substituent at a ring carbon tied to Figure Ia), while allowing wide modifications at peripheral groups.

---

How do the dependent claims narrow scope (and where are the “escape gaps”)?

Answer: Dependent claims progressively narrow R2 classes, linker X, Y substitution patterns, stereochemical constraints, and salt forms. Because dependent claims do not delete alternatives from Claim 1, they mostly add fallback positions that survive validity attacks and provide narrower infringement “hooks” if the broad genus is attacked.

Dependent claim narrowing map (high-signal)

• Claim 2: restricts R2 to the enumerated big set that excludes some R2 subtypes present in Claim 1’s broader wording (tightening the R2 genus list).
• Claims 3-5: focus R2 specifically to NRbRc, then narrow the NRbRc ring definition via heterocycle size/substituent limitations and constrain Rc options (including halogen-substituted phenyl).
• Claims 6-10: narrow R2 to:
  • alkyl/fluoroalkyl/CF3/hydroxyalkyl or specific -(alkyl)hetAr1 / -(alkyl)NH(alkyl) types (Claim 6)
  • hetAr2 or hetCyc1/hetCyc2 (Claim 7)
  • phenyl optionally substituted with NHSO2(alkyl) (Claim 8)
  • cycloalkyl with limited substituents (Claim 9)
  • carbonyl substituents C(=O)NReRf or C(=O)ORg (Claim 10)
• Claims 11-14: restrict X:
  • Claim 11 defines X as null/CH2/CH2CH2
  • Claim 12 sets X = CH2
  • Claim 13 sets X = CH2O
  • Claim 14 sets X = CH2NRd
• Claims 15-17: restrict Y to specific phenyl substitution sets (halogen, alkoxy, CF3, CHF2) or to N/S-heteroaryl with optional halogens.
• Claim 18: introduces an explicit absolute configuration of Figure Ia, anchoring stereochemistry for that subset.
• Claims 19-31: narrow R3, R1, and the broader parameter bundle (including a specific structured condition with R1/R2/Y/X/R3/R4/n combinations).
• Claims 32: salt restriction to trifluoroacetate, sulfate, or hydrochloride.
• Claims 33: ties Formula I to a long list of specifically enumerated compounds (see below), creating strong “example-to-genus” alignment.

How “escape” could work legally (conceptual, not speculative)

A product might attempt to avoid literal coverage by:

• selecting Formula I variables outside the defined sets (e.g., using a linker X not in {null, CH2, CH2CH2, CH2O, CH2NRd})
• changing Y from the specified phenyl/heteroaryl classes or substituent sets
• using stereochemistry not matching Figure Ia (if claim is interpreted as requiring that configuration for covered embodiments)
• using salts not listed in Claim 32 (though Claim 1 still covers “pharmaceutically acceptable salt,” so Claim 32 mostly adds dependent coverage rather than removing scope)

However, the practical infringement posture is typically determined by whether the accused product lands squarely in the Claim 1 variable definitions, not by dependent claim ladders.

---

Which exact compound exemplars are explicitly listed in Claim 33, and why does it matter?

Answer: Claim 33 enumerates dozens of specific Formula I embodiments, many sharing the pyrazolo[1,5-a]pyrimidine core and the pyrrolidine-substituted motif, with variations in:

• aryl group on the pyrrolidine nitrogen substituent (2,5-difluorophenyl, 2-chloro-5-fluorophenyl, 3-fluorophenyl, etc.)
• substituents at the “urea/carboxamide” region (hydroxyazetidine carboxamide, piperazine carboxamide, pyridinone/picolinamide, etc.)
• stereochemical labels (R/S; and specific stereochemical forms such as (1S,3R), (1S,3S))

Why the exemplars expand enforceability

Enumerating specific embodiments in a method claim helps with:

• identifying likely commercial formulations/active ingredients used by the product of interest
• bolstering written-description and enablement arguments by showing multiple “working” members of the genus
• providing near-direct mapping targets for infringement and design-around analysis

High-level structure clusters in Claim 33 (representative)

1. “3-hydroxyazetidine-1-carboxamide” cluster tied to multiple aryl variants (2,5-difluorophenyl; 2-chloro-5-fluorophenyl; 3-fluorophenyl).
2. urea / dimethylurea / isobutyramide variants on the core scaffold.
3. piperazine / morpholine carboxamides on the core scaffold (including tert-butyl protected forms and hydrochloride salt forms for some).
4. pyridinone/picolinamide/isonicotinamide nicotinamide variants defining a heteroaryl “tail” consistent with the Y variable and/or R2 modifications.
5. cycloalkyl/hydroxycycloalkyl variants (cyclopentanecarboxamide, cyclobutanecarboxamide, cyclopropane-containing carboxamides and oxo-bridged forms).

Claim 33’s list is long enough that, for most real candidates, the accused structure can likely be matched to one of the listed embodiments or to a close Markush neighbor.

---

How strong is the patent estate for this chemical series: what else typically surrounds this claim set?

Answer: With only the text provided, the broader landscape cannot be reconstructed to a complete “same-family / continuations / continuations-in-part” map without bibliographic and prosecution history. The claim itself indicates a genus chemistry platform that usually appears with complementary:

• compound (composition and active ingredient) claims
• method-of-treatment claims in multiple dependent formats
• stereochemical claim coverage (absolute configuration)
• salt claim coverage
• additional method claims for specific indications (pain vs neurodegenerative vs cancer subtypes)

Within the claim text you provided, those typical satellite coverages are mirrored in:

• broad indication framing in Claim 1
• salt-specific dependent Claim 32
• stereochemical dependent Claim 18
• structural example enumeration in Claim 33

Practical takeaway: this patent’s method-of-use scope is broad, and if the same applicant/patent family includes compound claims to the Formula I structures, the enforcement leverage increases beyond method administration alone.

---

What patent “type” is 8,865,698 (method-of-use) and what does that mean for FDA and infringement risk?

Answer: It is a method-of-treatment patent directed to administration of covered Formula I compounds to treat specified diseases. For US generic/biosimilar-style regulatory paradigms (ANDAs, and for biologics the BLA pathway), method-of-use patents are typically listed in the Orange Book only when they are tied to an approved drug product and can be asserted against medical use.

FDA status linkage logic

• If a covered active ingredient is approved and listed in the Orange Book with this patent as a method-of-use entry, then generic applicants must certify to that patent (typically Paragraph IV if they seek launch before expiration).
• In litigation, the central question is whether the proposed generic product, when prescribed and administered for an indication in the patent, includes a covered Formula I compound embodiment (or a pharmaceutically acceptable salt) and uses a therapeutically effective amount within the claim.

Biosimilar angle

This is not a biologic patent claim text. It is directed to “compound of Formula I,” so biosimilar risk is not the main pathway; generic risk and label carve-outs are more relevant.

---

When does this patent lose exclusivity: how to compute the expiration and exclusivity stack?

Answer: The expiration date cannot be computed from claim text alone. US patent term depends on:

• filing date (and any priority date used under 35 USC 154)
• PTA adjustments (prosecution history specific)
• any terminal disclaimers
• potential pediatric exclusivity adjustments (if applicable)
• whether any regulatory exclusivity attaches (drug product exclusivity is separate from patent term)

Because those bibliographic data are not included, an exclusivity timeline cannot be produced without risking inaccuracy.

---

How would a Paragraph IV challenge typically attack a claim like this?

Answer: Standard defenses for a broad Markush genus method claim include:

• indefiniteness: whether the boundary of covered chemical space is clear enough for infringement
• written description and enablement: whether the specification supports the full breadth across multiple heterocycles, linkers, and tails
• anticipation/obviousness: whether earlier disclosures taught the same genus or overlapping subsets
• lack of utility (rare) and overbreadth as a practical validity theme

Claim-specific friction points:

• The genus is broad across R2 and multiple ring sizes (4-8 membered heterocycles and bridged systems), which increases enablement exposure if the spec only demonstrates a limited subset.
• The presence of a stereochemical “absolute configuration of Figure Ia” in dependent claim 18 can create arguments about whether the spec supports all stereochemical variants across the full Markush breadth.

---

What generic entry risks exist under a method-of-use claim?

Answer: For a generic to infringe a method-of-use claim, a court typically evaluates:

• whether the generic has the same active ingredient identity (compound/salt)
• whether the generic is used to treat one of the claimed indications
• whether the practicing physician provides the “therapeutically effective amount” using normal dosing regimens

Risk reducers for generic manufacturers:

• label restrictions (carve-outs) to remove use for the claimed indications, if legally feasible
• design-around at the chemical level: selecting non-covered Formula I embodiments outside the Markush definitions
• settlement via licensing: paying to launch later or limiting indications

---

Comparison: what does the claim language cover that many competitor products may not?

Answer: Many competitor products in this class may differ in:

• specific aryl substitutions on Y (halogen/CF3/CHF2/alkoxy patterns)
• linker X position (null vs CH2 vs CH2CH2 vs CH2O vs CH2NRd)
• stereochemical configuration and ring substitution on the azetidine/hydroxyl ring region tied to Figure Ia
• selection of R2 tails, especially carbonyl-substituted (C(=O)NReRf / C(=O)ORg) or NRbRc heterocycle variants

If a competitor changes any of those variables outside the claim set, it can reduce literal coverage. If they remain within the Markush definitions, the claim is difficult to avoid without a licensing strategy.

---

How to use this patent in litigation and licensing strategy (actionable mapping)

Answer: 8,865,698 is best treated as an enforcement anchor for:

1. Active ingredient identity: map the accused API to Claim 1 Formula I variables and/or Claim 33 enumerated exemplars.
2. Indication match: confirm that the asserted use is within {pain, cancer, inflammation, neurodegenerative disease, T. cruzi}.
3. Salt and form: check whether the marketed API is a covered pharmaceutically acceptable salt; Claim 32 adds specific salts but does not limit Claim 1’s acceptable salt language.
4. Stereochemistry: if the product differs from Figure Ia absolute configuration, evaluate whether the court treats that requirement as restricting certain embodiments only or as part of the covered genus interpretation.

Licensing leverage: because Claim 1 is broad, it tends to support earlier settlements where the accused product is within the Formula I chemical space even if dosing regimens vary by indication.

---

Key Takeaways

• US Patent 8,865,698 is a broad method-of-treatment claim anchored to a large Markush-style “Formula I” genus of small molecules, with multiple therapeutic indications in Claim 1.
• The claim breadth is driven by wide permissible ranges for R2, Y, and linker X, plus multiple heterocycle constructors (4- to 8-membered N-containing rings and bridged variants).
• Dependent claims create fallback narrowing positions for R2 classes, X variants, Y substitution patterns, stereochemical configuration (Figure Ia), and specific salt types (trifluoroacetate, sulfate, hydrochloride).
• Claim 33 enumerates many specific exemplar compounds, improving mapping ability for infringement analysis and written-description alignment.
• For generic risk, the principal question is whether the generic product’s API falls within Formula I (or matches listed exemplars) and whether physicians practice a claimed indication using a therapeutically effective amount.

---

FAQs

1) Does a method-of-use claim like 8,865,698 require the generic to be the exact same salt form?
Claim 1 covers “a pharmaceutically acceptable salt,” while Claim 32 adds specific salts (trifluoroacetate, sulfate, hydrochloride) as dependent coverage.

2) What is the practical impact of Claim 18’s “absolute configuration of Figure Ia”?
It creates a dependent embodiment tied to a specific stereochemical configuration, which can matter if an accused product uses a different stereochemical form.

3) Can a label carve-out avoid infringement of a method-of-use patent?
Typically yes only if the carved-out labeling legally prevents physicians from practicing the claimed method for the carved indication and if enforcement standards accept the carve-out.

4) Which part of Formula I most often determines whether a product is “in” or “out” of the claim?
The variable definitions for R2 (tail) and Y (aryl/heteroaryl) and the linker X are the most decisive for literal scope mapping.

5) Why does Claim 33’s long list of exemplars matter for challenge and defense?
It provides multiple concrete members of the genus, which supports infringement mapping and strengthens the specification-to-genus narrative typically needed for validity defense.

---

References

1. US Patent 8,865,698 (claims text provided in prompt).

Drugs Protected by US Patent 8,865,698

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bayer Hlthcare	VITRAKVI	larotrectinib sulfate	CAPSULE;ORAL	210861-001	Nov 26, 2018		RX	Yes	No	8,865,698					METHOD OF TREATING CANCEROUS SOLID TUMORS
Bayer Hlthcare	VITRAKVI	larotrectinib sulfate	CAPSULE;ORAL	210861-002	Nov 26, 2018		RX	Yes	Yes	8,865,698					METHOD OF TREATING CANCEROUS SOLID TUMORS
Bayer Healthcare	VITRAKVI	larotrectinib sulfate	SOLUTION;ORAL	211710-001	Nov 26, 2018		RX	Yes	Yes	8,865,698					METHOD OF TREATING CANCEROUS SOLID TUMORS

International Family Members for US Patent 8,865,698

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3106463		301033	Netherlands
European Patent Office	3106463		PA2020504	Lithuania
European Patent Office	3106463		CA 2020 00013	Denmark
European Patent Office	3106463		122020000012	Germany